This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
RUXCOVID was a randomized, double-blind, parallel-group phase 3 trial evaluating ruxolitinib 5 mg versus placebo in patients with COVID-19 associated cytokine storm. The registry reports 432 enrolled participants, two treatment arms, one primary binary endpoint, and statistical analyses using logistic regression, a Cox proportional-hazards model, and ANCOVA.
| Feature | RUXCOVID |
|---|---|
| Trial name | RUXCOVID |
| Brief title | Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm |
| Phase | Phase 3 |
| Condition | Cytokine Storm (Covid-19) |
| Design | Randomized, double-blind, parallel-group |
| Primary purpose | Treatment |
| Interventions | Ruxolitinib 5 mg and placebo |
| Enrollment | 432 |
| Primary endpoint type | Binary |
| Hypothesis type | Superiority |
| Results posted | Yes |
| Statistical analyses posted | 17 |
| Lead sponsor | Novartis Pharmaceuticals |
2. Clinical Question
The primary statistical question was whether ruxolitinib 5 mg differed from placebo with respect to the proportion of patients who died, developed respiratory failure requiring mechanical ventilation, or required intensive care unit care during Day 1 through Day 29.
Population
Patients enrolled in the phase 3 RUXCOVID trial with COVID-19 associated cytokine storm.
Intervention
Ruxolitinib 5 mg.
Comparator
Placebo.
Primary question
Does ruxolitinib 5 mg produce a different proportion of patients experiencing the registered composite clinical outcome over Day 1 through Day 29?
3. Trial Design
Ruxolitinib
- Ruxolitinib 5 mg
- Randomized treatment assignment
- Double-blind trial design
- Compared with placebo
Placebo
- Placebo
- Randomized treatment assignment
- Double-blind trial design
- Compared with ruxolitinib 5 mg
4. Endpoints
| Endpoint | Time frame | Type | Analysis reported |
|---|---|---|---|
| Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care | Day 1 - Day 29 | Binary | Logistic regression |
| Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status | Baseline, Day 15, Day 29 | Binary | Logistic regression |
| Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status | Baseline, Day 15, Day 29 | Binary | Logistic regression |
| Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status | Baseline, Day 15, Day 29 | Binary | Logistic regression |
| Time to Improvement in Clinical Status | 29 days | Time-to-event | Cox proportional-hazards model |
| Mean Change From Baseline in the Clinical Status | Baseline, Day 15, Day 29 | Continuous | ANCOVA |
| Mortality Rate | Day 15, Day 29 | Binary | Logistic regression |
| Proportion of Patients Requiring Mechanical Ventilation | Day 1 - Day 29 | Binary | Logistic regression |
| Duration of Hospitalization | 29 days | Time-to-event | Cox proportional-hazards model |
| Time to Hospital Discharge or to a NEWS2 Score of ≤2 | 29 days | Time-to-event | Cox proportional-hazards model |
| Proportion of Patients With no Oxygen Therapy | Day 15, Day 29 | Binary | Logistic regression |
5. Statistical Methodology
The registry reports three main statistical method families for RUXCOVID: logistic regression for binary outcomes, a Cox proportional-hazards model for time-to-event outcomes, and ANCOVA for the continuous clinical-status change endpoint.
Logistic regression for binary outcomes
The primary endpoint is binary: a participant either experiences the specified composite outcome during the registered time frame or does not. Logistic regression models the odds of the binary outcome and expresses the treatment comparison as an odds ratio.
An OR of 1 represents equal odds under the model. An OR below 1 indicates lower estimated odds in the ruxolitinib 5 mg group; an OR above 1 indicates higher estimated odds.
Cox proportional-hazards model
The registry uses a proportional-hazards model for time to improvement in clinical status, duration of hospitalization, and time to hospital discharge or to a NEWS2 score of ≤2. These analyses use a hazard ratio as the effect measure.
For the posted time-to-event analyses, the registry states that a hazard ratio greater than 1 favors the ruxolitinib 5 mg arm. A hazard ratio is not a probability, a risk ratio, or a difference in median time.
ANCOVA for change in clinical status
ANCOVA was used for the continuous endpoint Mean Change From Baseline in the Clinical Status. The registry reports the effect as a least-squares mean, normalized here as a mean difference between treatment groups.
A value near zero indicates little estimated difference in mean change between the groups under the fitted model. The sign must be interpreted in the context of how the clinical-status scale is coded.
Intention-to-treat principle
For mortality, the registry explicitly states that the analysis population includes all randomized participants, including those who did not receive any dose, according to the intent-to-treat principle, while excluding patients lost to follow-up. This preserves treatment assignment as the basis for the randomized comparison.
Competing-risk framework
For the time to improvement in clinical status, duration of hospitalization, and time to hospital discharge or to a NEWS2 score of ≤2, the registry notes that the between-group comparison used a competing-risk framework. This matters because a participant may experience a competing event that prevents the event of primary interest from occurring in the same way.
6. Results: Primary Endpoint
The primary analysis compared ruxolitinib 5 mg with placebo for the registered composite endpoint over Day 1 through Day 29. The analysis population consisted of randomized participants excluding those who developed respiratory failure and/or required ICU care at randomization.
Odds ratio for the primary composite endpoint
95% CI: 0.48–1.73 · P = 0.769
Two-sided superiority analysis; logistic regression
The estimated odds ratio of 0.91 means that the modeled odds of experiencing the composite endpoint were estimated to be approximately 9% lower with ruxolitinib 5 mg than with placebo. This is a relative comparison of odds, not a statement that 9% fewer patients experienced the outcome and not a 9-percentage-point absolute risk reduction.
The 95% confidence interval of 0.48–1.73 is fairly wide relative to the point estimate and includes 1.00. Thus, the reported estimate is compatible with lower or higher odds under the statistical uncertainty represented by the interval. The interval describes uncertainty around the estimated treatment effect; it does not describe the range of individual patient outcomes.
The P-value of 0.769 is a measure of how compatible the observed data are with the null hypothesis under the specified statistical framework. It does not measure the size, clinical importance, or probability of the treatment effect. A large P-value is not evidence that the treatment effects are exactly equal.
The analysis is also specific to the stated analysis population and cumulative Day 1 through Day 29 composite endpoint. Because the endpoint combines death, respiratory failure requiring mechanical ventilation, and ICU care, the overall odds ratio does not identify which component, if any, drives the observed estimate.
7. Secondary Binary Outcomes
The registry reports several secondary binary analyses. Most use logistic regression and odds ratios, with assessments at Day 15 and Day 29 where specified. These endpoints should be read individually rather than treating their nominal P-values as if they were a single prespecified confirmatory test.
| Outcome | Time | OR | 95% CI | P-value |
|---|---|---|---|---|
| At least two-point improvement in clinical status | Day 15 | 0.89 | 0.55–1.46 | 0.647 |
| At least two-point improvement in clinical status | Day 29 | 1.00 | 0.52–1.92 | 0.997 |
| At least one-point improvement in clinical status | Day 15 | 0.98 | 0.51–1.87 | 0.946 |
| At least one-point improvement in clinical status | Day 29 | 0.79 | 0.35–1.79 | 0.573 |
| At least one-point deterioration in clinical status | Day 15 | 0.75 | 0.31–1.83 | 0.532 |
| At least one-point deterioration in clinical status | Day 29 | 1.18 | 0.40–3.49 | 0.764 |
| Mortality rate | Day 15 | 0.94 | 0.20–5.57 | 0.944 |
| Mortality rate | Day 29 | 1.21 | 0.35–5.11 | 0.775 |
| Requiring mechanical ventilation | Day 1 - Day 29 | 0.99 | 0.45–2.21 | 0.987 |
| No oxygen therapy | Day 15 | 0.61 | 0.23–1.63 | 0.325 |
| No oxygen therapy | Day 29 | 1.22 | 0.25–5.40 | — |
8. Time-to-Event Results
Three secondary endpoints were analyzed using a proportional-hazards model with a competing-risk framework. These analyses answer questions about the relative rate at which an event occurs over time rather than simply whether an event occurred by a fixed date.
| Endpoint | HR | 95% CI | P-value | Registry direction |
|---|---|---|---|---|
| Time to Improvement in Clinical Status | 1.11 | 0.90–1.37 | 0.330 | HR > 1 favors ruxolitinib 5 mg |
| Duration of Hospitalization | 1.04 | 0.84–1.28 | 0.738 | HR > 1 favors ruxolitinib 5 mg |
| Time to Hospital Discharge or to a NEWS2 Score of ≤2 | 1.02 | 0.84–1.23 | 0.869 | HR > 1 favors ruxolitinib 5 mg |
Time to Improvement in Clinical Status
Hazard ratio
95% CI: 0.90–1.37 · P = 0.330
The estimate of 1.11 corresponds to an approximately 11% higher estimated instantaneous rate of improvement in the ruxolitinib 5 mg group under the fitted model. The confidence interval spans both values below and above 1, so the estimate has substantial uncertainty. The P-value does not quantify the size of the estimated difference.
Duration of Hospitalization
Hazard ratio
95% CI: 0.84–1.28 · P = 0.738
The registry uses a competing-risk framework for this analysis and states that an HR greater than 1 favors ruxolitinib 5 mg. An estimate of 1.04 is therefore close to the no-difference value of 1.00 on the reported hazard-ratio scale.
Time to Hospital Discharge or to a NEWS2 Score of ≤2
Hazard ratio
95% CI: 0.84–1.23 · P = 0.869
The estimated hazard ratio is close to 1.00, with a confidence interval that includes 1.00. The analysis therefore does not establish a precise directional difference from the registry's reported estimate and uncertainty interval.
9. Continuous Clinical-Status Outcome
The registry also reports the mean change from baseline in clinical status using ANCOVA. Two analyses correspond to the two specified post-baseline time points.
| Time point | Effect measure | Mean difference | 95% CI | P-value |
|---|---|---|---|---|
| Day 15 | LS mean | -0.03 | -0.31–0.25 | 0.831 |
| Day 29 | LS mean | 0.08 | -0.23–0.38 | 0.624 |
Day 15
ANCOVA mean difference
95% CI: -0.31–0.25 · P = 0.831
The estimated between-group difference in least-squares mean change was -0.03. The confidence interval extends from -0.31 to 0.25, crossing zero. The statistical interpretation therefore depends on the scale's direction as well as the model-based estimate; the ClinicalTrials.gov record does not provide the scale coding needed to translate the sign into a clinical-status direction.
Day 29
ANCOVA mean difference
95% CI: -0.23–0.38 · P = 0.624
At Day 29, the estimated mean difference was 0.08, with a 95% confidence interval from -0.23 to 0.38. Because the interval includes zero, the data represented by this analysis are compatible with differences in either direction around the point estimate.
10. Statistical Methods Explained
Why was logistic regression used for the primary endpoint?
The primary endpoint is binary: the composite outcome either occurred or did not occur during the registered Day 1 through Day 29 period. Logistic regression is designed for this structure and produces an odds ratio comparing the modeled odds between the randomized treatment groups.
What does an odds ratio of 0.91 mean?
An OR of 0.91 means the estimated odds in the ruxolitinib 5 mg group were about 9% lower than the estimated odds in the placebo group. It does not mean the probability of the event was 9% lower. Odds and probabilities are related but are not interchangeable, particularly when outcomes are not rare.
Why is the confidence interval more informative than the point estimate alone?
The point estimate is only one estimate of the treatment contrast. The 95% confidence interval of 0.48–1.73 for the primary endpoint shows how uncertain that estimate is within the stated statistical framework. A point estimate of 0.91 by itself could give a misleading impression of precision.
What does the P-value of 0.769 tell us?
The P-value describes the compatibility of the observed data with the null hypothesis under the specified model and testing framework. It is not the probability that the null hypothesis is true, and it is not a measure of treatment magnitude. Effect size and uncertainty should be read from the odds ratio and confidence interval.
Why was a Cox proportional-hazards model used?
The registry classifies time to improvement in clinical status, duration of hospitalization, and time to hospital discharge or to a NEWS2 score of ≤2 as time-to-event outcomes. A Cox model allows treatment groups to be compared through a hazard ratio while accounting for the timing of events and censoring.
What does a hazard ratio of 1.11 mean?
For time to improvement in clinical status, the registry reports an HR of 1.11. Because the registry states that HR values above 1 favor ruxolitinib 5 mg for this analysis, the estimate corresponds to an approximately 11% higher modeled instantaneous rate of improvement. It does not mean that patients improve 11% faster in a simple arithmetic sense, nor does it imply an 11-percentage-point increase in the probability of improvement.
Why does the competing-risk framework matter?
The registry states that the between-group comparisons for the reported time-to-event outcomes used a competing-risk framework. When another event can prevent the event of interest from occurring in the same way, ordinary time-to-event reasoning can require modification. The competing-risk framework explicitly recognizes that structure rather than treating every participant as if all possible event pathways were interchangeable.
11. Secondary Outcome Interpretation
Clinical-status improvement
The two-point improvement estimates were 0.89 at Day 15 and 1.00 at Day 29. Their confidence intervals were 0.55–1.46 and 0.52–1.92, respectively.
Clinical-status deterioration
The one-point deterioration estimates were 0.75 at Day 15 and 1.18 at Day 29, with confidence intervals of 0.31–1.83 and 0.40–3.49.
Mortality
The reported odds ratios were 0.94 at Day 15 and 1.21 at Day 29. Both confidence intervals are wide: 0.20–5.57 and 0.35–5.11.
Mechanical ventilation
The reported odds ratio was 0.99, with a 95% CI of 0.45–2.21 and a P-value of 0.987.
Several of the secondary binary estimates have confidence intervals spanning relatively broad ranges. This is especially important when interpreting rare outcomes such as mortality, where the odds-ratio scale can become statistically unstable and imprecise. The point estimate should therefore not be separated from its confidence interval.
12. Safety Results
The registry data provide serious adverse events by randomized treatment arm as affected participants over the stated at-risk counts.
| Safety measure | Ruxolitinib 5 mg | Placebo |
|---|---|---|
| Serious adverse events | 31/281 | 15/143 |
These counts should be read as reported rather than converted into percentages. The denominators differ from the overall enrollment figure of 432, so the serious-adverse-event counts should not be interpreted as though all 432 enrolled participants formed the denominator for this particular safety summary.
13. Analysis Populations
| Endpoint / analysis | Analysis population |
|---|---|
| Primary composite endpoint | Randomized participants excluding those who developed respiratory failure and/or required ICU at randomization. |
| Clinical-status improvement and deterioration | Randomized participants with a valid assessment of clinical status at baseline. |
| Time to improvement in clinical status | Randomized participants with a valid assessment of clinical status at baseline. |
| Mean change from baseline in clinical status | Randomized participants with a valid assessment for the outcome measure. |
| Mortality rate | All randomized participants including those who did not receive any dose, as per intent-to-treat principle, and excluding patients lost to follow-up. |
| Mechanical ventilation, hospitalization, discharge/NEWS2, oxygen therapy | Randomized participants with a valid assessment for the outcome measure. |
This distinction is important. The randomized population is the foundation of an intention-to-treat comparison, but individual endpoint analyses can have different valid-assessment requirements. Consequently, an effect estimate for one endpoint should not automatically be assumed to have exactly the same analysis population as every other endpoint.
14. Multiplicity and Multiple Secondary Endpoints
The registry reports one primary endpoint and multiple secondary analyses. The ClinicalTrials.gov record identifies the hypothesis type as superiority but do not provide an alpha-spending scheme, multiplicity adjustment procedure, or endpoint hierarchy for the secondary analyses.
| Feature | What the ClinicalTrials.gov record establishes |
|---|---|
| Primary endpoint | One registered binary composite endpoint |
| Primary hypothesis type | Superiority |
| Secondary analyses | Multiple binary, continuous, and time-to-event outcomes |
| Statistical methods | Logistic regression, Cox proportional-hazards model, ANCOVA |
| Multiplicity adjustment | Not reported in the ClinicalTrials.gov record |
| Alpha-spending procedure | Not reported in the ClinicalTrials.gov record |
Accordingly, the secondary P-values should be interpreted as the P-values attached to their individual reported analyses. Without a documented multiplicity strategy in the ClinicalTrials.gov record, they should not automatically be interpreted as establishing independent confirmatory findings across the entire collection of secondary endpoints.
15. Confidence Intervals and Precision
The RUXCOVID results illustrate why confidence intervals are essential when interpreting effect estimates.
| Outcome | Estimate | 95% CI | Null value |
|---|---|---|---|
| Primary composite endpoint | OR 0.91 | 0.48–1.73 | 1.00 |
| Two-point improvement, Day 15 | OR 0.89 | 0.55–1.46 | 1.00 |
| Two-point improvement, Day 29 | OR 1.00 | 0.52–1.92 | 1.00 |
| Time to improvement | HR 1.11 | 0.90–1.37 | 1.00 |
| Mean change, Day 15 | -0.03 | -0.31–0.25 | 0 |
| Mean change, Day 29 | 0.08 | -0.23–0.38 | 0 |
For odds ratios and hazard ratios, the conventional null value is 1. For a mean difference, the null value is 0. Several of the reported intervals include their corresponding null values, which is consistent with the reported two-sided P-values being above conventional significance thresholds. More importantly, the widths of the intervals show that a point estimate should not be treated as a precise measurement of the underlying treatment effect.
16. What the Odds Ratio Does — and Does Not — Mean
The primary odds ratio of 0.91 means that the modeled odds of the composite endpoint were approximately 9% lower in the ruxolitinib 5 mg group than in the placebo group.
It does not mean that the probability of the composite endpoint was exactly 9% lower, that 9% of participants benefited, or that every patient experienced the same proportional change.
The 95% CI of 0.48–1.73 indicates considerable uncertainty around the primary odds-ratio estimate. Because it includes 1.00, the data represented by the analysis are compatible with odds lower than, close to, or higher than the placebo group under the specified model.
The P-value of 0.769 should not be interpreted as a 76.9% probability that there is no treatment effect. Nor does it indicate that the treatment effect is small. Effect magnitude is described by the estimate; statistical precision is described by the confidence interval; the P-value addresses compatibility with a null hypothesis under the specified testing framework.
17. Reading the Time-to-Event Analyses
Time-to-event endpoints contain more information than a simple yes/no assessment because they incorporate the timing of events. A participant who experiences an event early and one who experiences it later are not treated as identical observations when the analysis properly uses event times.
The RUXCOVID registry analyses use Cox proportional-hazards models and report hazard ratios. The proportional-hazards assumption is therefore an important model consideration. If the relative hazard changes materially over time, a single hazard ratio can become a less complete summary of the treatment contrast.
Hazard ratio
A relative measure of the instantaneous event rate under the fitted Cox model. It is not the same as a risk ratio or absolute time difference.
Censoring
Time-to-event analyses can use information up to the point at which a participant's event status is no longer observed, subject to the assumptions of the analysis.
Competing risks
The registry explicitly identifies a competing-risk framework for the reported time-to-event comparisons.
Kaplan-Meier
Kaplan-Meier estimation is a standard descriptive method for time-to-event distributions. The registry-reported RUXCOVID method fields specifically identify Cox proportional-hazards modeling rather than reporting a Kaplan-Meier analysis.
18. Missing Data and Assessment Requirements
The ClinicalTrials.gov record does not specify a detailed imputation strategy, such as multiple imputation, last observation carried forward, or a prespecified missing-not-at-random sensitivity analysis.
What the registry does specify is that several analyses require participants to have a valid assessment for the relevant outcome, while the mortality analysis explicitly uses an intention-to-treat population and excludes patients lost to follow-up. These distinctions matter because excluding participants with unavailable outcome assessments can change the population contributing information to an analysis.
19. Randomization and Blinding
Participants were assigned to one of two parallel treatment groups.
The registry classifies the trial as double-blind.
The primary purpose is registered as treatment.
The posted statistical analyses are identified as superiority analyses.
Randomization is the key design feature supporting a causal comparison between treatment assignments, provided the randomized comparison is analyzed appropriately. Double blinding provides an additional design safeguard against differential behavior or assessment based on knowledge of assignment.
20. Trial Timeline
Trial start
The registry lists May 2, 2020 as the study start date.
Primary completion
The registry lists October 17, 2020 as the primary completion date.
Registry status
The RUXCOVID study is listed as completed, with results posted on ClinicalTrials.gov.
21. Statistical Profile of the Reported Results
| Analysis family | RUXCOVID use | Reported effect measure |
|---|---|---|
| Logistic regression | Primary composite and multiple binary secondary outcomes | Odds ratio |
| Cox proportional-hazards model | Time to improvement, duration of hospitalization, discharge/NEWS2 endpoint | Hazard ratio |
| ANCOVA | Mean change from baseline in clinical status | Mean difference / LS mean |
This combination of methods is coherent with the endpoint structures reported in the registry: binary outcomes are modeled as categorical responses, time-to-event outcomes use a survival-analysis model, and the continuous change-from-baseline endpoint uses a linear-model approach.
22. Important Limitations and Interpretation Issues
- Composite endpoint: the primary endpoint combines death, respiratory failure requiring mechanical ventilation, and ICU care. A single odds ratio summarizes the composite and does not establish which component contributes most to the overall estimate.
- Analysis population: the primary analysis excludes participants who had developed respiratory failure and/or required ICU care at randomization, so the primary estimate is not simply a comparison across every randomized participant.
- Endpoint-specific populations: several secondary analyses require valid outcome assessments, meaning their analysis populations can differ from the population used for the mortality ITT analysis.
- Odds ratio versus risk: the reported odds ratios should not be restated as risk ratios or absolute risk differences without the underlying event probabilities.
- Confidence-interval width: several secondary outcomes have wide confidence intervals, particularly mortality, indicating substantial statistical uncertainty around their point estimates.
- Multiplicity: the ClinicalTrials.gov record does not specify a multiplicity-adjustment strategy for the secondary analyses. Individual nominal P-values therefore require appropriate caution when considered collectively.
- Cox assumptions: the hazard-ratio analyses depend on the proportional-hazards model. A single HR can be an incomplete summary if relative hazards vary materially over time.
- Competing risks: the registry explicitly identifies a competing-risk framework for the reported time-to-event comparisons, so the HRs should be understood within that analytical structure.
- Missing-data details: the ClinicalTrials.gov record identifies valid-assessment requirements and an ITT mortality population but do not provide a detailed imputation strategy.
- Safety denominators: serious adverse events are reported as 31/281 and 15/143, rather than using the overall enrollment denominator of 432.
23. Why This Trial Matters Statistically
RUXCOVID is a useful teaching case because it combines three major clinical-trial analysis frameworks in one randomized phase 3 study: logistic regression for binary outcomes, Cox proportional-hazards modeling for time-to-event outcomes, and ANCOVA for continuous change from baseline.
| Concept | How it appears in RUXCOVID |
|---|---|
| Randomization | Randomized, parallel-group phase 3 design |
| Blinding | Double-blind study |
| Binary endpoint | Primary composite endpoint over Day 1 - Day 29 |
| Logistic regression | Primary and multiple secondary binary analyses |
| Odds ratio | Primary effect measure and secondary binary effect measure |
| Confidence interval | Reported around the odds ratios, hazard ratios, and mean differences |
| P-value | Reported for the primary and secondary analyses |
| Time-to-event analysis | Time to improvement, hospitalization, and discharge/NEWS2 outcomes |
| Cox model | Used for reported time-to-event analyses |
| Hazard ratio | Effect measure for time-to-event outcomes |
| Competing risks | Used for the reported between-group time-to-event comparisons |
| ANCOVA | Mean change from baseline in clinical status |
| Intention-to-treat | Explicitly identified for mortality analysis |
| Safety analysis | Serious adverse events reported by treatment arm |
24. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The primary logistic-regression analysis produced an odds ratio of 0.91 with a 95% CI of 0.48–1.73 and a P-value of 0.769. The interval includes the null value of 1.00, and the estimate should be interpreted together with its uncertainty.
Endpoint interpretation
The secondary analyses address several distinct dimensions of clinical status, including improvement, deterioration, mortality, mechanical ventilation, hospitalization, discharge/NEWS2 status, oxygen therapy, and continuous change in clinical status.
Model interpretation
Odds ratios, hazard ratios, and ANCOVA mean differences describe different mathematical contrasts. They should not be placed on a common scale or interpreted as interchangeable measures of treatment effect.
Safety interpretation
The serious-adverse-event counts of 31/281 and 15/143 provide a separate safety description and should be interpreted independently of the efficacy estimates.
25. Statistical Methods Summary
| Question | Method | Effect measure |
|---|---|---|
| Did the primary binary composite outcome differ between treatment groups? | Logistic regression | OR 0.91 (95% CI 0.48–1.73) |
| Did the odds of binary clinical outcomes differ? | Logistic regression | Odds ratios |
| Did the rate of reaching a time-to-event endpoint differ? | Cox proportional-hazards model | Hazard ratios |
| Did mean clinical status change differ? | ANCOVA | Mean difference / LS mean |
26. Related Tutorials
Learn more about the methods used in this trial:
27. Related Calculators
28. Sources
- ClinicalTrials.gov: RUXCOVID, NCT04362137.
- Linked publication: PubMed record for PMID 35368384: 35368384.
Continue through Clinical Biostats
Use the related tutorials and statistical calculators to explore the regression, survival-analysis, confidence-interval, and clinical-trial concepts represented in RUXCOVID.
29. Record Summary
RUXCOVID provides a compact example of how different clinical-trial endpoint structures require different statistical models. The primary composite endpoint is binary and was analyzed with logistic regression, producing an odds ratio of 0.91 with a 95% CI of 0.48–1.73 and a P-value of 0.769. Secondary outcomes extend the analysis to binary clinical-status measures, mortality, mechanical ventilation, oxygen therapy, continuous change from baseline, and several time-to-event endpoints analyzed with Cox proportional-hazards models using a competing-risk framework.
The most important statistical lesson is that the estimates cannot be interpreted in isolation. Odds ratios describe binary-outcome odds, hazard ratios describe modeled instantaneous event rates, and ANCOVA estimates describe differences in adjusted mean change. Confidence intervals quantify uncertainty around each estimate, while P-values address compatibility with a null hypothesis rather than treatment magnitude. Analysis populations also differ by endpoint, making it important to identify exactly which participants contributed to each reported comparison.